Securities Exchange Act

United States. Securities and Exchange Commission

Portola Pharmaceuticals Receives Notice of Termination for Clinical Collaboration Agreement with Bayer

Portola Pharmaceuticals, Inc. recently received written notice of termination from Bayer AG for a Clinical Collaboration Agreement dated February 1, 2016. This termination allows Portola to regain full rights in Japan for the development and commercialization of andexanet alfa, a reversal agent for Factor Xa inhibitors. The notice was given